Biovaxys Technology Corp Stock Fundamentals
| BVAXF Stock | USD 0.04 0 5.24% |
Biovaxys Technology Corp fundamentals help investors to digest information that contributes to Biovaxys Technology's financial success or failures. It also enables traders to predict the movement of Biovaxys OTC Stock. The fundamental analysis module provides a way to measure Biovaxys Technology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biovaxys Technology otc stock.
Biovaxys |
Biovaxys Technology Corp OTC Stock Shares Outstanding Analysis
Biovaxys Technology's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Biovaxys Technology Shares Outstanding | 106.72 M |
Most of Biovaxys Technology's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biovaxys Technology Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Biovaxys Technology Corp has 106.72 M of shares currently outstending. This is 40.89% lower than that of the Healthcare sector and about the same as Biotechnology (which currently averages 106.85 M) industry. The shares outstanding for all United States stocks is 81.34% higher than that of the company.
Biovaxys Technology Corp Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biovaxys Technology's current stock value. Our valuation model uses many indicators to compare Biovaxys Technology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biovaxys Technology competition to find correlations between indicators driving Biovaxys Technology's intrinsic value. More Info.Biovaxys Technology Corp is rated below average in return on equity category among its peers. It is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biovaxys Technology's earnings, one of the primary drivers of an investment's value.Biovaxys Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biovaxys Technology's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Biovaxys Technology could also be used in its relative valuation, which is a method of valuing Biovaxys Technology by comparing valuation metrics of similar companies.Biovaxys Technology is currently under evaluation in shares outstanding category among its peers.
Biovaxys Fundamentals
| Return On Equity | -0.73 | |||
| Return On Asset | -0.38 | |||
| Current Valuation | 11.35 M | |||
| Shares Outstanding | 106.72 M | |||
| Shares Owned By Insiders | 18.94 % | |||
| Price To Earning | (4.32) X | |||
| Price To Book | 2.53 X | |||
| EBITDA | (6.44 M) | |||
| Net Income | (6.46 M) | |||
| Cash And Equivalents | 39.05 K | |||
| Current Ratio | 0.16 X | |||
| Book Value Per Share | 0.06 X | |||
| Cash Flow From Operations | (5.29 M) | |||
| Earnings Per Share | (0.05) X | |||
| Number Of Employees | 17 | |||
| Beta | -0.59 | |||
| Market Capitalization | 8.73 M | |||
| Total Asset | 8.5 M | |||
| Retained Earnings | (80 M) | |||
| Working Capital | 35 M | |||
| Current Asset | 37 M | |||
| Current Liabilities | 2 M | |||
| Z Score | -7.8 | |||
| Net Asset | 8.5 M |
About Biovaxys Technology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biovaxys Technology Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biovaxys Technology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biovaxys Technology Corp based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320 and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. BIOVAXYS TECHNOLOGY is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Biovaxys OTC Stock
Biovaxys Technology financial ratios help investors to determine whether Biovaxys OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biovaxys with respect to the benefits of owning Biovaxys Technology security.